R B Aylward

Summary

Affiliation: World Health Organization
Country: Switzerland

Publications

  1. doi request reprint The global polio eradication initiative: lessons learned and prospects for success
    Bruce Aylward
    World Health Organization, Avenue Appia 20, 1211 Geneva 27, Switzerland
    Vaccine 29:D80-5. 2011
  2. ncbi request reprint Risk management in a polio-free world
    R Bruce Aylward
    Global Polio Eradication Initiative, World Health Organization, Geneva, Switzerland
    Risk Anal 26:1441-8. 2006
  3. ncbi request reprint Eradicating polio: today's challenges and tomorrow's legacy
    R B Aylward
    Global Polio Eradication Initiative, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland
    Ann Trop Med Parasitol 100:401-13. 2006
  4. ncbi request reprint Interrupting poliovirus transmission -- new solutions to an old problem
    R Bruce Aylward
    Global Polio Eradication Initiative, WHO, 20 Avenue Appia, Geneva 1211, Switzerland
    Biologicals 34:133-9. 2006
  5. pmc The human story
    R Bruce Aylward
    World Health Organization, 20 Avenue Appia, CH 1211 Geneva 27, Switzerland
    BMJ 331:1261-2. 2005
  6. ncbi request reprint Policy. OPV cessation--the final step to a "polio-free" world
    R Bruce Aylward
    Global Polio Eradication Initiative, World Health Organization, Geneva 27 Switzerland
    Science 310:625-6. 2005
  7. pmc Polio eradication: mobilizing and managing the human resources
    R Bruce Aylward
    Polio Eradication Initiative, World Health Organization, Geneva, Switzerland
    Bull World Health Organ 83:268-73. 2005
  8. pmc Can we capitalize on the virtues of vaccines? Insights from the polio eradication initiative
    R Bruce Aylward
    Polio Eradication Initiative, World Health Organization, 20, Avenue Appia, CH 1211 Geneva 27, Switzerland
    Am J Public Health 95:773-7. 2005
  9. pmc Disease eradication as a public health strategy: a case study of poliomyelitis eradication
    R B Aylward
    Expanded Programme on Immunization, Vaccines and Biologicals, World Health Organization, Geneva, Switzerland
    Bull World Health Organ 78:285-97. 2000
  10. pmc Framework for evaluating the risks of paralytic poliomyelitis after global interruption of wild poliovirus transmission
    R Bruce Aylward
    World Health Organization, Geneva, Switzerland
    Bull World Health Organ 82:40-6. 2004

Detail Information

Publications28

  1. doi request reprint The global polio eradication initiative: lessons learned and prospects for success
    Bruce Aylward
    World Health Organization, Avenue Appia 20, 1211 Geneva 27, Switzerland
    Vaccine 29:D80-5. 2011
    ....
  2. ncbi request reprint Risk management in a polio-free world
    R Bruce Aylward
    Global Polio Eradication Initiative, World Health Organization, Geneva, Switzerland
    Risk Anal 26:1441-8. 2006
    ....
  3. ncbi request reprint Eradicating polio: today's challenges and tomorrow's legacy
    R B Aylward
    Global Polio Eradication Initiative, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland
    Ann Trop Med Parasitol 100:401-13. 2006
    ....
  4. ncbi request reprint Interrupting poliovirus transmission -- new solutions to an old problem
    R Bruce Aylward
    Global Polio Eradication Initiative, WHO, 20 Avenue Appia, Geneva 1211, Switzerland
    Biologicals 34:133-9. 2006
    ....
  5. pmc The human story
    R Bruce Aylward
    World Health Organization, 20 Avenue Appia, CH 1211 Geneva 27, Switzerland
    BMJ 331:1261-2. 2005
  6. ncbi request reprint Policy. OPV cessation--the final step to a "polio-free" world
    R Bruce Aylward
    Global Polio Eradication Initiative, World Health Organization, Geneva 27 Switzerland
    Science 310:625-6. 2005
    ..This Policy Forum reviews the feasibility and implications of eventually stopping the use of live polio vaccines...
  7. pmc Polio eradication: mobilizing and managing the human resources
    R Bruce Aylward
    Polio Eradication Initiative, World Health Organization, Geneva, Switzerland
    Bull World Health Organ 83:268-73. 2005
    ....
  8. pmc Can we capitalize on the virtues of vaccines? Insights from the polio eradication initiative
    R Bruce Aylward
    Polio Eradication Initiative, World Health Organization, 20, Avenue Appia, CH 1211 Geneva 27, Switzerland
    Am J Public Health 95:773-7. 2005
    ....
  9. pmc Disease eradication as a public health strategy: a case study of poliomyelitis eradication
    R B Aylward
    Expanded Programme on Immunization, Vaccines and Biologicals, World Health Organization, Geneva, Switzerland
    Bull World Health Organ 78:285-97. 2000
    ..When the humanitarian, economic and consequent benefits of this initiative are measured against the costs, a strong argument is made for eradication as a valuable disease control strategy...
  10. pmc Framework for evaluating the risks of paralytic poliomyelitis after global interruption of wild poliovirus transmission
    R Bruce Aylward
    World Health Organization, Geneva, Switzerland
    Bull World Health Organ 82:40-6. 2004
    ..However, this framework must be regarded as a dynamic tool, requiring regular updating as additional information on these risks becomes available through further scientific research, programmatic work, and policy decisions...
  11. ncbi request reprint Global health goals: lessons from the worldwide effort to eradicate poliomyelitis
    R Bruce Aylward
    Global Polio Eradication Initiative, Department of Vaccines and Biologicals, Geneva, Switzerland
    Lancet 362:909-14. 2003
    ..The greatest threats to poliomyelitis eradication are a financing gap of US 210 million dollars and difficulties in strategy implementation in at most five countries...
  12. ncbi request reprint A global call for new polio vaccines
    David L Heymann
    Global Polio Eradication Initiative, World Health Organization, 20 Avenue Appia, CH 1211 Geneva, Switzerland
    Nature 434:699-700. 2005
  13. ncbi request reprint Eradicating polio
    David L Heymann
    Polio Eradication Initiative, World Health Organization, Geneva
    N Engl J Med 351:1275-7. 2004
  14. pmc Perspectives from the global poliomyelitis eradication initiative
    H F Hull
    World Health Organization, Geneva, Switzerland
    Bull World Health Organ 76:42-6. 1998
    ..Careful consideration should be given in the planning phases of a disease control initiative on how the initiative can be used to support other health initiatives...
  15. pmc Eradication of poliomyelitis in countries affected by conflict
    R H Tangermann
    World Health Organization, Geneva, Switzerland
    Bull World Health Organ 78:330-8. 2000
    ..The goal of polio eradication by the end of 2000 remains attainable if supplementary immunization and surveillance can be accelerated in countries affected by conflict...
  16. ncbi request reprint Progress towards global polio eradication
    H F Hull
    Department of Vaccines and Biologicals, World Health Organization, 1211, Geneva, Switzerland
    Vaccine 19:4378-84. 2001
    ..With global eradication imminent, WHO is preparing for post-eradication issues: containment of polioviruses, certification of eradication, and stopping immunization...
  17. ncbi request reprint A vision of a world without polio: the OPV cessation strategy
    David L Heymann
    World Health Organization, 20 Avenue Appia, CH 1211 Geneva 27, Switzerland
    Biologicals 34:75-9. 2006
    ..Final preparations for the eventual global and simultaneous cessation of OPV will require the same level of international cooperation and coordination that has brought the world to the verge of polio eradication...
  18. doi request reprint Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine: a randomised, double-blind, controlled trial
    Roland W Sutter
    World Health Organization, Geneva, Switzerland
    Lancet 376:1682-8. 2010
    ..Poliovirus types 1 and 3 co-circulate in poliomyelitis-endemic countries. We aimed to assess the immunogenicity of a novel bivalent types 1 and 3 oral poliovirus vaccine (bOPV)...
  19. ncbi request reprint Poliomyelitis eradication and pandemic influenza
    David L Heymann
    Polio Eradication Initiative, World Health Organization, Geneva 27, Switzerland
    Lancet 367:1462-4. 2006
  20. ncbi request reprint Dangerous pathogens in the laboratory: from smallpox to today's SARS setbacks and tomorrow's polio-free world
    David L Heymann
    Polio Eradication InitiativeWHO, Geneva 1211, Switzerland
    Lancet 363:1566-8. 2004
  21. ncbi request reprint Mass vaccination: when and why
    D L Heymann
    World Health Organization, Geneva, Switzerland
    Curr Top Microbiol Immunol 304:1-16. 2006
    ..In the twenty-first century, mass vaccination and routine immunization remain a necessary alliance for attaining both national and international goals in the control of vaccine preventable disease...
  22. ncbi request reprint New strategies for the elimination of polio from India
    Nicholas C Grassly
    Department of Infectious Disease Epidemiology, Imperial College London, Norfolk Place, London, UK
    Science 314:1150-3. 2006
    ..We analyze strategies to counteract this and show that switching to monovalent vaccine may finally interrupt virus transmission...
  23. ncbi request reprint Development and consideration of global policies for managing the future risks of poliovirus outbreaks: insights and lessons learned through modeling
    Kimberly M Thompson
    Kids Risk Project, Harvard School of Public Health, 677 Huntington Ave, 3rd Floor, Boston, MA 02115, USA
    Risk Anal 26:1571-80. 2006
    ..This analytical journey has provided several key insights and lessons learned that will be useful to future analysts involved in similar complex decision-making processes...
  24. ncbi request reprint Protective efficacy of a monovalent oral type 1 poliovirus vaccine: a case-control study
    Nicholas C Grassly
    Department of Infectious Disease Epidemiology, Imperial College London, London, UK
    Lancet 369:1356-62. 2007
    ..A high-potency monovalent oral type 1 poliovirus vaccine (mOPV1) was developed in 2005 to tackle persistent poliovirus transmission in the last remaining infected countries. Our aim was to assess the efficacy of this vaccine in India...
  25. pmc The risks, costs, and benefits of possible future global policies for managing polioviruses
    Kimberly M Thompson
    Kids Risk Project, Harvard School of Public Health, 677 Huntington Ave, Third Floor, Boston, MA 02115, USA
    Am J Public Health 98:1322-30. 2008
    ..We assessed the costs, risks, and benefits of possible future major policy decisions on vaccination, surveillance, response plans, and containment following global eradication of wild polioviruses...
  26. doi request reprint Effectiveness of immunization against paralytic poliomyelitis in Nigeria
    Helen E Jenkins
    Medical Research Council Centre for Outbreak Analysis and Modeling, Department of Infectious Disease Epidemiology, Faculty of Medicine, Imperial College London, London, United Kingdom
    N Engl J Med 359:1666-74. 2008
    ..Understanding the relative contribution of these vaccines and the improved coverage to the decline in incident cases is essential for future planning...
  27. ncbi request reprint The polio eradication endgame. As polio eradication nears realization, such real-world vaccination strategies could hold lessons for the future in AIDS vaccine development
    David L Heymann
    IAVI Rep 10:13-7. 2006
  28. ncbi request reprint Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication
    Radboud J Duintjer Tebbens
    Kids Risk Project, Harvard School of Public Health, Boston, MA, USA
    Risk Anal 26:1471-505. 2006
    ..This article attempts to comprehensively characterize the risks, synthesize the existing data available for modeling them, and present quantitative risk estimates that can provide a starting point for informing policy decisions...